Share Price and Basic Stock Data
Last Updated: December 27, 2025, 8:45 pm
| PEG Ratio | 117.71 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ERIS Lifesciences Ltd operates in the pharmaceuticals sector, focusing on the development and commercialization of specialty and generic medicines. As of September 2023, the company’s share price stood at ₹1,526, with a market capitalization of ₹20,785 Cr. The company demonstrated significant revenue growth, with sales rising from ₹1,347 Cr in FY 2022 to ₹1,685 Cr in FY 2023, and further projected to reach ₹2,009 Cr in FY 2024. In the trailing twelve months (TTM), revenue reported was ₹2,998 Cr, indicating a robust upward trajectory. Quarterly sales figures show a consistent increase, with ₹467 Cr in June 2023 and ₹505 Cr in September 2023, culminating in ₹551 Cr for March 2024. This growth can be attributed to strong demand for ERIS’s products and effective market strategies, positioning the company favorably within a competitive landscape.
Profitability and Efficiency Metrics
ERIS Lifesciences has maintained solid profitability metrics, with a reported net profit of ₹449 Cr in TTM. The operating profit margin (OPM) stood at an impressive 36%, reflecting efficient cost management and strong pricing power. For FY 2023, the operating profit was ₹539 Cr, and in FY 2024, it is expected to rise to ₹677 Cr. However, the company has faced fluctuations in profitability, with the net profit margin declining from 30.12% in FY 2022 to 22.20% in FY 2023. The interest coverage ratio stood at 4.48x, indicating that earnings are sufficient to cover interest obligations, though it has decreased from 20.94x in FY 2023, suggesting increased leverage. The return on equity (ROE) and return on capital employed (ROCE) were reported at 12.9% and 12.2%, respectively, which are moderate compared to industry averages, suggesting room for improvement in capital efficiency.
Balance Sheet Strength and Financial Ratios
ERIS Lifesciences’ balance sheet reveals a mix of strengths and challenges. Total assets stood at ₹6,744 Cr as of March 2025, while total liabilities were ₹6,734 Cr, indicating a thin margin of asset coverage. The company reported reserves of ₹3,078 Cr, providing a cushion for future investments and operational needs. However, borrowings increased significantly from ₹877 Cr in FY 2023 to ₹2,478 Cr in FY 2025, raising concerns about financial leverage. The current ratio was reported at 0.88, slightly below the typical sector range, indicating potential liquidity constraints. The price-to-book value (P/BV) ratio stood at 6.76x, suggesting that the stock is trading at a premium compared to its book value. In contrast, the enterprise value (EV) to EBITDA ratio was reported at 21.16, indicating that the stock may be overvalued relative to its earnings potential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of ERIS Lifesciences reflects a stable investor base, with promoters holding 54.85% of the shares as of March 2025. This level of promoter ownership generally instills confidence in the market. Domestic institutional investors (DIIs) accounted for 19.36%, while foreign institutional investors (FIIs) held 7.21%, indicating moderate interest from international investors. Over the past year, promoter holdings have remained relatively stable, suggesting confidence in the company’s long-term prospects. However, FIIs have reduced their stake from 15.50% in December 2022 to 7.21% in March 2025, which could signal caution among foreign investors regarding the company’s growth trajectory. The total number of shareholders increased from 42,245 in September 2023 to 59,438 in March 2025, indicating growing retail interest and confidence in the company’s future.
Outlook, Risks, and Final Insight
Looking ahead, ERIS Lifesciences faces both opportunities and challenges. The company is well-positioned to capitalize on the growing demand for pharmaceutical products, supported by its strong sales performance and operational efficiencies. However, rising borrowings and a declining interest coverage ratio pose risks to financial stability. Additionally, the volatility in profit margins suggests that maintaining profitability will require continued focus on cost management and strategic pricing. If the company can effectively navigate these challenges while leveraging its strengths, it may enhance shareholder value and further solidify its market position. The potential for expansion into new markets and product lines remains a crucial factor for growth, making it imperative for ERIS to balance risk with opportunity as it progresses into future fiscal periods.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,105.46 Cr | 1,149.90 | 52.70 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 399 | 461 | 423 | 403 | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 |
| Expenses | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 |
| Operating Profit | 129 | 151 | 137 | 119 | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 |
| OPM % | 32% | 33% | 32% | 30% | 36% | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% |
| Other Income | 3 | 5 | 2 | 1 | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 |
| Interest | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 |
| Depreciation | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 |
| Profit before tax | 101 | 121 | 107 | 76 | 112 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 |
| Tax % | 8% | 1% | 6% | 19% | 17% | 3% | 12% | -4% | 22% | 25% | 25% | 21% | 22% |
| Net Profit | 93 | 119 | 100 | 61 | 94 | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 |
| EPS in Rs | 6.96 | 8.85 | 7.49 | 4.81 | 6.98 | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 |
Last Updated: August 20, 2025, 11:05 am
Below is a detailed analysis of the quarterly data for ERIS Lifesciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 773.00 Cr.. The value appears strong and on an upward trend. It has increased from 705.00 Cr. (Mar 2025) to 773.00 Cr., marking an increase of 68.00 Cr..
- For Expenses, as of Jun 2025, the value is 496.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 453.00 Cr. (Mar 2025) to 496.00 Cr., marking an increase of 43.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 277.00 Cr.. The value appears strong and on an upward trend. It has increased from 252.00 Cr. (Mar 2025) to 277.00 Cr., marking an increase of 25.00 Cr..
- For OPM %, as of Jun 2025, the value is 36.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 36.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 54.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 5.00 Cr..
- For Depreciation, as of Jun 2025, the value is 71.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 77.00 Cr. (Mar 2025) to 71.00 Cr., marking a decrease of 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 32.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 22.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 125.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2025) to 125.00 Cr., marking an increase of 23.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 8.66. The value appears strong and on an upward trend. It has increased from 6.89 (Mar 2025) to 8.66, marking an increase of 1.77.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:24 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 2,998 |
| Expenses | 414 | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 1,931 |
| Operating Profit | 95 | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,068 |
| OPM % | 19% | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% |
| Other Income | 9 | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | 19 |
| Interest | 0 | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 210 |
| Depreciation | 5 | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 298 |
| Profit before tax | 98 | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 579 |
| Tax % | 28% | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% | |
| Net Profit | 71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 449 |
| EPS in Rs | 5,121.45 | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 30.52 |
| Dividend Payout % | -0% | -0% | 63% | -0% | -0% | -0% | 13% | 21% | 20% | 26% | -0% | 28% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.35% | 51.69% | 82.96% | 19.43% | -1.36% | 2.06% | 19.53% | 14.37% | -7.88% | 6.15% | -5.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 26.33% | 31.28% | -63.53% | -20.79% | 3.42% | 17.47% | -5.16% | -22.25% | 14.03% | -11.69% |
ERIS Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 22% |
| 3 Years: | 29% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 4% |
| 3 Years: | -5% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 37% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 18% |
| 3 Years: | 16% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 3:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:13 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.14 | 0.14 | 0.14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 176 | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,078 |
| Borrowings | 1 | 1 | 0 | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,389 |
| Other Liabilities | 94 | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,412 | 1,680 |
| Total Liabilities | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,160 |
| Fixed Assets | 75 | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,217 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 122 |
| Investments | 84 | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 68 |
| Other Assets | 112 | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,304 | 1,753 |
| Total Assets | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,160 |
Below is a detailed analysis of the balance sheet data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,078.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,841.00 Cr. (Mar 2025) to 3,078.00 Cr., marking an increase of 237.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,478.00 Cr. (Mar 2025) to 2,389.00 Cr., marking a decrease of 89.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,680.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,412.00 Cr. (Mar 2025) to 1,680.00 Cr., marking an increase of 268.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,160.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,744.00 Cr. (Mar 2025) to 7,160.00 Cr., marking an increase of 416.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,217.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,306.00 Cr. (Mar 2025) to 5,217.00 Cr., marking a decrease of 89.00 Cr..
- For CWIP, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 55.00 Cr..
- For Investments, as of Sep 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,753.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,304.00 Cr. (Mar 2025) to 1,753.00 Cr., marking an increase of 449.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,160.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,744.00 Cr. (Mar 2025) to 7,160.00 Cr., marking an increase of 416.00 Cr..
Notably, the Reserves (3,078.00 Cr.) exceed the Borrowings (2,389.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 94.00 | 117.00 | 172.00 | 268.00 | -55.00 | 169.00 | 372.00 | 424.00 | 405.00 | -338.00 | 675.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 |
| Inventory Days | 166 | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 |
| Days Payable | 138 | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 |
| Cash Conversion Cycle | 43 | 97 | 102 | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 48 | 59 |
| Working Capital Days | 7 | 15 | 9 | 23 | -13 | -17 | 59 | 64 | 75 | 50 | -296 | -49 |
| ROCE % | 64% | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 6,482,100 | 2.72 | 1034.15 | N/A | N/A | N/A |
| HDFC Hybrid Equity Fund | 2,459,629 | 1.59 | 392.41 | N/A | N/A | N/A |
| Franklin India Small Cap Fund | 1,866,828 | 2.2 | 297.83 | N/A | N/A | N/A |
| DSP Small Cap Fund | 1,230,000 | 1.15 | 196.23 | N/A | N/A | N/A |
| Franklin India Flexi Cap Fund | 1,224,569 | 0.98 | 195.37 | N/A | N/A | N/A |
| UTI Flexi Cap Fund | 1,217,751 | 0.76 | 194.28 | 2,573,067 | 2025-12-07 01:12:50 | -52.67% |
| Franklin India Opportunities Fund | 771,388 | 1.48 | 123.07 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 675,000 | 0.37 | 107.69 | N/A | N/A | N/A |
| HDFC Multi Cap Fund | 675,000 | 0.54 | 107.69 | N/A | N/A | N/A |
| UTI Mid Cap Fund | 643,678 | 0.85 | 102.69 | 627,981 | 2025-12-15 01:01:34 | 2.5% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 25.85 | 28.82 | 28.10 | 29.89 | 26.16 |
| Diluted EPS (Rs.) | 25.81 | 28.79 | 28.07 | 29.88 | 26.14 |
| Cash EPS (Rs.) | 50.67 | 42.61 | 36.12 | 34.61 | 29.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 209.57 | 190.11 | 163.30 | 140.35 | 116.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 209.57 | 190.11 | 163.30 | 140.35 | 116.10 |
| Revenue From Operations / Share (Rs.) | 212.46 | 147.70 | 123.92 | 99.10 | 89.25 |
| PBDIT / Share (Rs.) | 76.03 | 51.36 | 40.29 | 37.60 | 32.35 |
| PBIT / Share (Rs.) | 52.87 | 37.94 | 31.68 | 32.84 | 29.19 |
| PBT / Share (Rs.) | 35.89 | 31.70 | 29.76 | 32.53 | 29.05 |
| Net Profit / Share (Rs.) | 27.50 | 29.19 | 27.51 | 29.85 | 26.16 |
| NP After MI And SOA / Share (Rs.) | 25.83 | 28.82 | 28.10 | 29.88 | 26.16 |
| PBDIT Margin (%) | 35.78 | 34.77 | 32.51 | 37.93 | 36.24 |
| PBIT Margin (%) | 24.88 | 25.68 | 25.56 | 33.13 | 32.70 |
| PBT Margin (%) | 16.89 | 21.46 | 24.01 | 32.82 | 32.55 |
| Net Profit Margin (%) | 12.94 | 19.76 | 22.20 | 30.12 | 29.30 |
| NP After MI And SOA Margin (%) | 12.15 | 19.50 | 22.67 | 30.14 | 29.30 |
| Return on Networth / Equity (%) | 12.32 | 15.15 | 17.40 | 21.28 | 22.52 |
| Return on Capital Employeed (%) | 12.74 | 11.42 | 13.36 | 21.53 | 23.76 |
| Return On Assets (%) | 5.00 | 5.56 | 10.42 | 17.87 | 19.35 |
| Long Term Debt / Equity (X) | 0.60 | 0.25 | 0.29 | 0.02 | 0.00 |
| Total Debt / Equity (X) | 0.84 | 1.06 | 0.37 | 0.02 | 0.00 |
| Asset Turnover Ratio (%) | 0.41 | 0.37 | 0.52 | 0.61 | 0.67 |
| Current Ratio (X) | 0.88 | 0.90 | 1.73 | 3.14 | 2.80 |
| Quick Ratio (X) | 0.64 | 0.83 | 1.43 | 2.55 | 2.23 |
| Inventory Turnover Ratio (X) | 11.05 | 1.11 | 1.26 | 1.31 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 28.43 | 0.00 | 26.15 | 20.10 | 21.02 |
| Dividend Payout Ratio (CP) (%) | 14.99 | 0.00 | 20.01 | 17.34 | 18.75 |
| Earning Retention Ratio (%) | 71.57 | 0.00 | 73.85 | 79.90 | 78.98 |
| Cash Earning Retention Ratio (%) | 85.01 | 0.00 | 79.99 | 82.66 | 81.25 |
| Interest Coverage Ratio (X) | 4.48 | 8.24 | 20.94 | 123.26 | 243.78 |
| Interest Coverage Ratio (Post Tax) (X) | 2.62 | 5.68 | 15.30 | 98.87 | 198.08 |
| Enterprise Value (Cr.) | 21908.96 | 13413.39 | 8575.56 | 9359.51 | 8168.96 |
| EV / Net Operating Revenue (X) | 7.57 | 6.68 | 5.09 | 6.95 | 6.74 |
| EV / EBITDA (X) | 21.16 | 19.20 | 15.65 | 18.31 | 18.60 |
| MarketCap / Net Operating Revenue (X) | 6.67 | 5.70 | 4.62 | 6.95 | 6.77 |
| Retention Ratios (%) | 71.56 | 0.00 | 73.84 | 79.89 | 78.97 |
| Price / BV (X) | 6.76 | 4.42 | 3.54 | 4.91 | 5.21 |
| Price / Net Operating Revenue (X) | 6.67 | 5.70 | 4.62 | 6.95 | 6.77 |
| EarningsYield | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 |
After reviewing the key financial ratios for ERIS Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 25.85. This value is within the healthy range. It has decreased from 28.82 (Mar 24) to 25.85, marking a decrease of 2.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is 25.81. This value is within the healthy range. It has decreased from 28.79 (Mar 24) to 25.81, marking a decrease of 2.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 50.67. This value is within the healthy range. It has increased from 42.61 (Mar 24) to 50.67, marking an increase of 8.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 209.57. It has increased from 190.11 (Mar 24) to 209.57, marking an increase of 19.46.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 209.57. It has increased from 190.11 (Mar 24) to 209.57, marking an increase of 19.46.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 212.46. It has increased from 147.70 (Mar 24) to 212.46, marking an increase of 64.76.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.03. This value is within the healthy range. It has increased from 51.36 (Mar 24) to 76.03, marking an increase of 24.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 52.87. This value is within the healthy range. It has increased from 37.94 (Mar 24) to 52.87, marking an increase of 14.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 35.89. This value is within the healthy range. It has increased from 31.70 (Mar 24) to 35.89, marking an increase of 4.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 27.50. This value is within the healthy range. It has decreased from 29.19 (Mar 24) to 27.50, marking a decrease of 1.69.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 25.83. This value is within the healthy range. It has decreased from 28.82 (Mar 24) to 25.83, marking a decrease of 2.99.
- For PBDIT Margin (%), as of Mar 25, the value is 35.78. This value is within the healthy range. It has increased from 34.77 (Mar 24) to 35.78, marking an increase of 1.01.
- For PBIT Margin (%), as of Mar 25, the value is 24.88. This value exceeds the healthy maximum of 20. It has decreased from 25.68 (Mar 24) to 24.88, marking a decrease of 0.80.
- For PBT Margin (%), as of Mar 25, the value is 16.89. This value is within the healthy range. It has decreased from 21.46 (Mar 24) to 16.89, marking a decrease of 4.57.
- For Net Profit Margin (%), as of Mar 25, the value is 12.94. This value exceeds the healthy maximum of 10. It has decreased from 19.76 (Mar 24) to 12.94, marking a decrease of 6.82.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.15. This value is within the healthy range. It has decreased from 19.50 (Mar 24) to 12.15, marking a decrease of 7.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.32. This value is below the healthy minimum of 15. It has decreased from 15.15 (Mar 24) to 12.32, marking a decrease of 2.83.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.74. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 12.74, marking an increase of 1.32.
- For Return On Assets (%), as of Mar 25, the value is 5.00. This value is within the healthy range. It has decreased from 5.56 (Mar 24) to 5.00, marking a decrease of 0.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.60, marking an increase of 0.35.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.84. This value is within the healthy range. It has decreased from 1.06 (Mar 24) to 0.84, marking a decrease of 0.22.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has increased from 0.37 (Mar 24) to 0.41, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1.5. It has decreased from 0.90 (Mar 24) to 0.88, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 1. It has decreased from 0.83 (Mar 24) to 0.64, marking a decrease of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.05. This value exceeds the healthy maximum of 8. It has increased from 1.11 (Mar 24) to 11.05, marking an increase of 9.94.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 28.43. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 28.43, marking an increase of 28.43.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 14.99. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 14.99, marking an increase of 14.99.
- For Earning Retention Ratio (%), as of Mar 25, the value is 71.57. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 71.57, marking an increase of 71.57.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 85.01. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 85.01, marking an increase of 85.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.48. This value is within the healthy range. It has decreased from 8.24 (Mar 24) to 4.48, marking a decrease of 3.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.62. This value is below the healthy minimum of 3. It has decreased from 5.68 (Mar 24) to 2.62, marking a decrease of 3.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 21,908.96. It has increased from 13,413.39 (Mar 24) to 21,908.96, marking an increase of 8,495.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.57. This value exceeds the healthy maximum of 3. It has increased from 6.68 (Mar 24) to 7.57, marking an increase of 0.89.
- For EV / EBITDA (X), as of Mar 25, the value is 21.16. This value exceeds the healthy maximum of 15. It has increased from 19.20 (Mar 24) to 21.16, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.67. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 6.67, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 71.56. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 71.56, marking an increase of 71.56.
- For Price / BV (X), as of Mar 25, the value is 6.76. This value exceeds the healthy maximum of 3. It has increased from 4.42 (Mar 24) to 6.76, marking an increase of 2.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.67. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 6.67, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ERIS Lifesciences Ltd:
- Net Profit Margin: 12.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.74% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 50 (Industry average Stock P/E: 52.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.84
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Amit Bakshi | Chairperson & Managing Director |
| Mr. Krishnakumar Vaidyanathan | COO & Executive Director |
| Mr. Inderjeet Singh Negi | Executive Director |
| Mr. Kaushal Shah | Executive Director |
| Mr. Rajeev Dalal | Independent Director |
| Mr. Sujesh Vasudevan | Independent Director |
| Ms. Kalpana Unadkat | Independent Director |
| Mr. Prashant Gupta | Independent Director |
FAQ
What is the intrinsic value of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd's intrinsic value (as of 28 December 2025) is 1176.94 which is 22.87% lower the current market price of 1,526.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 20,785 Cr. market cap, FY2025-2026 high/low of 1,910/1,097, reserves of ₹3,078 Cr, and liabilities of 7,160 Cr.
What is the Market Cap of ERIS Lifesciences Ltd?
The Market Cap of ERIS Lifesciences Ltd is 20,785 Cr..
What is the current Stock Price of ERIS Lifesciences Ltd as on 28 December 2025?
The current stock price of ERIS Lifesciences Ltd as on 28 December 2025 is 1,526.
What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ERIS Lifesciences Ltd stocks is 1,910/1,097.
What is the Stock P/E of ERIS Lifesciences Ltd?
The Stock P/E of ERIS Lifesciences Ltd is 50.0.
What is the Book Value of ERIS Lifesciences Ltd?
The Book Value of ERIS Lifesciences Ltd is 227.
What is the Dividend Yield of ERIS Lifesciences Ltd?
The Dividend Yield of ERIS Lifesciences Ltd is 0.48 %.
What is the ROCE of ERIS Lifesciences Ltd?
The ROCE of ERIS Lifesciences Ltd is 12.2 %.
What is the ROE of ERIS Lifesciences Ltd?
The ROE of ERIS Lifesciences Ltd is 12.9 %.
What is the Face Value of ERIS Lifesciences Ltd?
The Face Value of ERIS Lifesciences Ltd is 1.00.